Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLC Published 2022-06-07 Download video MP4 360p Recommendations 05:20 Lung Cancer: 9 Common Treatment Options 07:44 Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of Care? (BMIC-024) 04:25 Durvalumab Tolerability in Non–Small Cell Lung Cancer 1:12:24 Management of Stage III Non Small Cell Lung Cancer_Dr Naveen Mummudi 04:46 5-year survival outcomes from the PACIFIC trial 02:47 The Mechanism of Action of Immunotherapy for Cancer Treatment 06:02 Near-death experiences kill the person that you used to be | Bruce Greyson 03:29 Faith and an Immunotherapy Clinical Trial: Barry's Lung Cancer Story 20:14 For HCPs: Data Update From IMFINZI® (durvalumab)’s PACIFIC Trial and Perspective from Dr Decker 06:07 PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC 1:11:21 Maximizing the Potential of Immunotherapy in Unresectable Stage III NSCLC 08:12 The MIRAGE Trial: MRI-Guided Versus CT-Guided SBRT for Prostate Cancer 17:46 Stage 4 Lung Cancer: Fighting for a 2nd Opinion (Squamous Cell Carcinoma) | Amy’s Story (1 of 3) 03:15 Optimal neoadjuvant IO in resectable stage III melanoma: interferon gamma signature analysis 03:53 Stages of Lung Cancer|Survival Rate & Prognosis of Lung Cancer|Dr.Sandeep Nayak & Dr.Sreekanth Reddy 17:01 Preparing a Patient for Treatment with IMFINZI® (durvalumab) 03:29 What is new in the treatment of DCIS? 1:10:25 How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC 02:46 Unanswered questions in treating lung cancer with immunotherapy 01:22 The personalization of neoadjuvant immunotherapy in stage III melanoma Similar videos 06:22 Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLC 03:53 [lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospital 03:25 Impact of radiation dose to immune cells in unresectable or stage III NSCLC in the durvalumab era 03:53 Locally Advanced NSCLC: The PACIFIC Trial 11:30 Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for ch... 06:47 Case 1: Immunotherapy in Locally Advanced NSCLC 02:10 Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC 02:53 HUDSON: Durvalumab combination therapies to overcome PD-L1 blockade resistance in advanced NSCLC 02:59 The Role of Immunotherapy for Unresectable Stage 3 NSCLC Mandarin Lung Cancer Video Library 05:54 Treating Unresectable Stage III NSCLC: A Focus on Stage IIIA Disease 06:19 Stage 3 Unresectable NSCLC 06:05 ITE inference: post-hoc analysis of clinical trials 01:00 Combining SABR and immunotherapies for NSCLC 2:04:01 abc Oncology Educational Course 2022 - Lung Cancer Module 01:48 Adjuvant and neoadjuvant chemo-IO for UK patients with NSCLC 09:36 Phases of Clinical Studies 1:08:00 Has Immunotherapy Brought Us to an Inflection Point in the Management of Stage I-III NSCLC? 1:05:26 NOS ASCO Review 2022 Lung Cancer Update More results